Dr. Mrinal M. Gounder, MD

Dr. Gounder practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Gounder's NPI, 1376758821, was assigned on May 10, 2007. Dr. Gounder graduated from SUNY Upstate Medical University in 2004. Dr. Gounder's New York license number on file is 247325.

Dr. Gounder's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Gounder's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Gounder to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gounder practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Gounder's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Gounder is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Gounder's licenses on file in 5 states: New York, Florida, New Jersey, North Carolina and Illinois.

Dmand AI lists lung cancer among the conditions Dr. Gounder treats.

CMS data shows 166 Medicare services from Dr. Gounder across 4 procedure codes in 2024, all of them office visits, for 72 Medicare patients. Medicare paid $18,205 for them. Every service was in an office.

CMS counts 72 Medicare patients who saw Dr. Gounder in 2024. The largest group is 65 to 74, with 38 patients. 72% of them have high blood pressure, and 68% have high cholesterol. Their average risk score is 2.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gounder's median patient age at 66, with 62% women.

In 2024, Dr. Gounder wrote 117 Medicare Part D claims for 34 patients. 62% of them were for generic drugs. CMS names the drug for 58 of them, across 3 drugs with 11 or more claims each, at $541,953 in total drug cost. In 2023, CMS named 41 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Gounder for performance year 2024, reported as part of a group. Dr. Gounder accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gounder as offering telehealth.

Dmand AI links 132 papers to Dr. Gounder, published from 2010 to 2025. 2019 was the busiest year, with 14. The most frequent topics are Antineoplastic Agents, Sarcoma and Maximum Tolerated Dose. Dr. Gounder has published most often in Clin Cancer Res. Dr. Gounder's most frequent co-authors are William D. Tap, MD, Mark A. Dickson, MD and Ping Chi, MD, PhD.

Dmand AI links Dr. Gounder to 14 clinical trials, 7 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Desmoid Tumors, Fibroma and Liposarcoma. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 75 general payments to Dr. Gounder from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $46,906. It also lists 3 research payments totaling $1,417 from 2016 to 2019.

Dr. Gounder graduated from SUNY Upstate Medical University in 2004.

Dr. Gounder is in network with 10 carriers, including Excellus BlueCross BlueShield, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.